Second, the TME in EGFR mutation‐driven lung cancer is poorly immunogenic, lacks infiltration of anti‐cancer immune effector cells, and shows poor response to anti‐PD‐1/PD‐L1 treatment. Here, EGFR is linked to lung carcinoma.